These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32641998)

  • 1. Indoxyl sulfate induces intestinal barrier injury through IRF1-DRP1 axis-mediated mitophagy impairment.
    Huang Y; Zhou J; Wang S; Xiong J; Chen Y; Liu Y; Xiao T; Li Y; He T; Li Y; Bi X; Yang K; Han W; Qiao Y; Yu Y; Zhao J
    Theranostics; 2020; 10(16):7384-7400. PubMed ID: 32641998
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption.
    Vaziri ND; Yuan J; Khazaeli M; Masuda Y; Ichii H; Liu S
    Am J Nephrol; 2013; 37(6):518-25. PubMed ID: 23689670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uremic Toxic Blood-Brain Barrier Disruption Mediated by AhR Activation Leads to Cognitive Impairment during Experimental Renal Dysfunction.
    Bobot M; Thomas L; Moyon A; Fernandez S; McKay N; Balasse L; Garrigue P; Brige P; Chopinet S; Poitevin S; Cérini C; Brunet P; Dignat-George F; Burtey S; Guillet B; Hache G
    J Am Soc Nephrol; 2020 Jul; 31(7):1509-1521. PubMed ID: 32527975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease.
    Ito S; Higuchi Y; Yagi Y; Nishijima F; Yamato H; Ishii H; Osaka M; Yoshida M
    J Leukoc Biol; 2013 Jun; 93(6):837-45. PubMed ID: 23362306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early elimination of uremic toxin ameliorates AKI-to-CKD transition.
    Chen JH; Chao CT; Huang JW; Hung KY; Liu SH; Tarng DC; Chiang CK
    Clin Sci (Lond); 2021 Dec; 135(23):2643-2658. PubMed ID: 34796904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Throughput Screen Identifies Host and Microbiota Regulators of Intestinal Barrier Function.
    Grosheva I; Zheng D; Levy M; Polansky O; Lichtenstein A; Golani O; Dori-Bachash M; Moresi C; Shapiro H; Del Mare-Roumani S; Valdes-Mas R; He Y; Karbi H; Chen M; Harmelin A; Straussman R; Yissachar N; Elinav E; Geiger B
    Gastroenterology; 2020 Nov; 159(5):1807-1823. PubMed ID: 32653496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uremic toxicity of indoxyl sulfate.
    Niwa T
    Nagoya J Med Sci; 2010 Feb; 72(1-2):1-11. PubMed ID: 20229698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120.
    Liu WC; Tomino Y; Lu KC
    Toxins (Basel); 2018 Sep; 10(9):. PubMed ID: 30208594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting protein-bound uremic toxins in chronic kidney disease.
    Niwa T
    Expert Opin Ther Targets; 2013 Nov; 17(11):1287-301. PubMed ID: 23941498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy?
    Yamaguchi J; Tanaka T; Inagi R
    Nephron; 2017; 135(3):201-206. PubMed ID: 27960172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the efficacy of AST-120 (KREMEZIN
    Asai M; Kumakura S; Kikuchi M
    Ren Fail; 2019 Nov; 41(1):47-56. PubMed ID: 30732506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of ABCG2 as an Exporter of Uremic Toxin Indoxyl Sulfate in Mice and as a Crucial Factor Influencing CKD Progression.
    Takada T; Yamamoto T; Matsuo H; Tan JK; Ooyama K; Sakiyama M; Miyata H; Yamanashi Y; Toyoda Y; Higashino T; Nakayama A; Nakashima A; Shinomiya N; Ichida K; Ooyama H; Fujimori S; Suzuki H
    Sci Rep; 2018 Jul; 8(1):11147. PubMed ID: 30042379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deleterious vascular effects of indoxyl sulfate and reversal by oral adsorbent AST-120.
    Six I; Gross P; Rémond MC; Chillon JM; Poirot S; Drueke TB; Massy ZA
    Atherosclerosis; 2015 Nov; 243(1):248-56. PubMed ID: 26408929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120.
    Niwa T
    Ther Apher Dial; 2011 Apr; 15(2):120-4. PubMed ID: 21426500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN-induced kinase 1-induced dynamin-related protein 1 Ser637 phosphorylation reduces mitochondrial fission and protects against intestinal ischemia reperfusion injury.
    Qasim W; Li Y; Sun RM; Feng DC; Wang ZY; Liu DS; Yao JH; Tian XF
    World J Gastroenterol; 2020 Apr; 26(15):1758-1774. PubMed ID: 32351292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease.
    Fujii H; Nakai K; Fukagawa M
    Ther Apher Dial; 2011 Apr; 15(2):125-8. PubMed ID: 21426501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indoxyl sulfate is a nephro-vascular toxin.
    Niwa T
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S2-6. PubMed ID: 20797565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated Drp1-mediated mitochondrial ROS influence the gut microbiome and intestinal barrier after hemorrhagic shock.
    Duan C; Kuang L; Xiang X; Zhang J; Zhu Y; Wu Y; Yan Q; Liu L; Li T
    Aging (Albany NY); 2020 Jan; 12(2):1397-1416. PubMed ID: 31954373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drp1 activates ROS/HIF-1α/EZH2 and triggers mitochondrial fragmentation to deteriorate hypercalcemia-associated neuronal injury in mouse model of chronic kidney disease.
    Sun H; Li X; Chen X; Xiong Y; Cao Y; Wang Z
    J Neuroinflammation; 2022 Sep; 19(1):213. PubMed ID: 36050772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction.
    Enoki Y; Watanabe H; Arake R; Fujimura R; Ishiodori K; Imafuku T; Nishida K; Sugimoto R; Nagao S; Miyamura S; Ishima Y; Tanaka M; Matsushita K; Komaba H; Fukagawa M; Otagiri M; Maruyama T
    J Cachexia Sarcopenia Muscle; 2017 Oct; 8(5):735-747. PubMed ID: 28608457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.